Chardan Capital Reiterates Buy on Achilles Therapeutics, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on Achilles Therapeutics (NASDAQ:ACHL) and maintained an $11 price target.
August 07, 2023 | 9:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has reiterated a 'Buy' rating on Achilles Therapeutics and maintained an $11 price target.
The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Achilles Therapeutics. The maintained price target of $11 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100